Lexaria Updates Fast-Moving GLP-1 'Arm's Race' Developments
Lexaria's strategy is to continue developing and optimizing our wholly-owned DehydraTECH™ drug delivery platform for application in the GLP-1 space, positioning it as a 'must-have' technology for ...
Compounded Versions Of Weight Loss And Diabetes Drugs Led To Death And Hospitalization, Novo Nordisk Says It Is Aware
Earlier, Novo Nordisk A/S (NYSE:NVO) petitioned the FDA to ban compounding pharmacies from producing cheaper, unapproved ...